Tel Aviv University
Dan Peer is a Full Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the upcoming Vice President for Research and Development at Tel Aviv University, the biggest Research University in Israel.
From 2016, he is the Chair of Tel Aviv University Cancer Biology Research Center that includes 17 affiliated hospitals and from 2017, the Founding and Managing Director of SPARK Tel Aviv, Center for Translational Medicine at TAU.
One of Prof. Peer’s manuscript is considered a hallmark paper (cited > 7,100 times) on nanocarriers in cancer therapeutics. He did pioneering work in the field of RNA therapeutics in immune cells using targeted nanocarriers and his lab was the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers as drug discovery tools in leukocytes. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA to cells to induce therapeutic gene expression of desired proteins that has important implications in cancer, inflammation and infection diseases. Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, six spin-off companies were generated aiming to bring innovative personalized molecular medicines into clinical practice using nanotechnology. Overall, based on his work more than 10 different clinical trials are currently being conducted.
Prof. Peer is a scientific advisory board member in more than 15 companies and on the scientific advisory board of 20 journals. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Past Member of the Board of the Israel Young Academy of Science.